Author:
Nasr Patrik,Jönsson Cecilia,Ekstedt Mattias,Kechagias Stergios
Abstract
Hepatic steatosis is caused by exaggerated hepatic lipid accumulation and is a common histological and radiological finding. Non-alcoholic fatty liver disease (NAFLD), or metabolic dysfunction associated steatotic liver disease (MASLD), is highly associated with metabolic syndrome and represents the most common cause of hepatic steatosis. However, since several comorbidities, lifestyle factors, and drugs can cause hepatic steatosis, MASLD is, to some extent, a diagnosis of exclusion. Nevertheless, initiatives have been taken to encompass positive (instead of negative) criteria for diagnosis - such as the presence of cardiometabolic risk factors together with hepatic steatosis. Nonetheless, before confirming a patient with MASLD, it is essential to map and evaluate other causes of fatty liver disease or steatotic liver disease. Several causes of hepatic steatosis have been identified in studies; however, the study cohorts are scarce and often anecdotal. Additionally, many studies have shown correlation without proving causation, and many are retrospective without reporting relevant patient characteristics and comorbidities - making it difficult to draw conclusions regarding the underlying etiology or present comorbidity of hepatic steatosis. In this narrative review, we aimed to identify and summarize present studies evaluating the impact of the most common and often suggested causes of hepatic steatosis.
Subject
Management of Technology and Innovation
Reference178 articles.
1. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
2. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
3. The global NAFLD epidemic
4. Rinella ME, Lazarus JV, Ratziu V. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(23)00418-X/fulltext [Last accessed on 23 Oct 2023]
5. Rinella ME, Lazarus JV, Ratziu V. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Available from: https://www.sciencedirect.com/science/article/pii/S1665268123002375 [Last accessed on 23 Oct 2023]
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献